Content Hub
NEWLY ADDED!
CAR-TCR: Article
CAR T: Fireside Chat
Helen Tayton- Martin, CBO, Adaptimmune
André Choulika, CEO,Cellectis
Michael Koslowski, CMO, GammaDelta Therapeutics
Dolores Schendel, CEO, Medigene
Jacob Plieth, Senior Reporter,Vantage Analysis
Presentations
NEWLY ADDED!
CAR-TCR Presentation
CAR T: Continuation in a Revolution of Cancer Therapeutics
Dr. Joseph McGuirk, Professor of Medicine Schutte Speas Professor of Hematology Oncology. Medical Director, BMT and Cellular Therapeutics. Division Director, Hematologic Malignancies and Cellular Therapeutics
NEWLY ADDED!
CAR-TCR Presentation
Overcoming Treatment
Resistance to T Cell
Therapy
Adrian Bot, M.D., Ph.D.
Vice President, Translational Medicine
NEWLY ADDED!
CAR-TCR Presentation
Navigating Regulatory Requirements for
Early Phase CAR-T Clinical Studies
Elena Spanjaard, Global Head of Regulatory Affairs, Celyad
NEWLY ADDED!
CAR-TCR Presentation
CAR T Cells for Solid Tumours, To Do List
Francesco M. Marincola, Chief Research Officer, Refuge Biotechnologies
NEWLY ADDED!
CAR-TCR Presentation
Identification of Novel Shared Targets for Solid Tumors
Hans-Peter Gerber, Ph.D. SVP & CSO,3T Biosciences
NEWLY ADDED!
CAR-TCR Presentation
Cross-Sector Efforts to Advance Gene & Cell Therapy Manufacturing
Michael Lehmicke, Director, Science & Industry Affairs
NEWLY ADDED!
CAR-TCR Presentation
The Bridge to Curative Cellular Therapies
Paul Rennert, CAR-TCR Summit 2019
NEWLY ADDED!
CAR-TCR Presentation
Next generation, contextual regulation of CAR T function in vivo:
Zhifen Yang, Senior Scientist, Refuge Biotechnologies
Magazines
NEWLY ADDED!
CAR-TCR Magazine - Q1
Interviews
NEWLY ADDED!
CAR-TCR Conversation with...
Laura Pierce, Biomedical Engineer, NIST
In this conversation, Laura expresses her opinions on the greatest challenges currently facing developers of cell therapies, as well as her thoughts on what the future might hold for CAR-TCR.
NEWLY ADDED!
CAR-TCR Conversation with...
Sarah Snykers, Quality Control Manager, Celyad
In this conversation, Sarah shares her thoughts on the best direction for cell therapy drug developers to take, in order to drive the progression of CAR-TCR treatments.
CAR-TCR Conversation with...
Peter Emtage, Senior Vice President, Head of Cell Therapy Research, Kite, a Gilead Company
In this conversation, Peter shares his views on the clinical and commercial progression of CAR-T therapies after a whirlwind few years.
CAR-TCR Conversation with...
David Sourdive, Executive Vice President, Technical Operations & Co-founder, Cellectis
In this conversation, David discusses the disruptive genetic engineering approaches developed to create efficacious, next generation CAR and TCR therapies.
Press Releases
Press Release: Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology
Industry Surveys
NEWLY ADDED!
CAR-TCR Industry Survey Results 2019
Here’s what your peers think about key developments and priorities in this rapidly evolving field.
CAR-TCR Industry Survey 2018
The infographic provides some great insights into solid tumor approaches, commercial impact and limitations of manufacturing strategies.
